JPWO2020148338A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020148338A5 JPWO2020148338A5 JP2021540589A JP2021540589A JPWO2020148338A5 JP WO2020148338 A5 JPWO2020148338 A5 JP WO2020148338A5 JP 2021540589 A JP2021540589 A JP 2021540589A JP 2021540589 A JP2021540589 A JP 2021540589A JP WO2020148338 A5 JPWO2020148338 A5 JP WO2020148338A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- residue
- mutated
- mutation
- replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 38
- 229920001184 polypeptide Polymers 0.000 claims 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims 35
- 101710181549 Interleukin-34 Proteins 0.000 claims 22
- 102100033499 Interleukin-34 Human genes 0.000 claims 22
- 230000035772 mutation Effects 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 108020001507 fusion proteins Proteins 0.000 claims 11
- 102000037865 fusion proteins Human genes 0.000 claims 11
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 8
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 6
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 5
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- 101000998132 Homo sapiens Interleukin-34 Proteins 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- -1 PTP-ζ Proteins 0.000 claims 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 3
- 102220603628 BPI fold-containing family A member 1_H56C_mutation Human genes 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024163874A JP2025000723A (ja) | 2019-01-15 | 2024-09-20 | 変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305046.5 | 2019-01-15 | ||
| EP19305046 | 2019-01-15 | ||
| PCT/EP2020/050920 WO2020148338A1 (en) | 2019-01-15 | 2020-01-15 | Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163874A Division JP2025000723A (ja) | 2019-01-15 | 2024-09-20 | 変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517029A JP2022517029A (ja) | 2022-03-03 |
| JPWO2020148338A5 true JPWO2020148338A5 (enrdf_load_stackoverflow) | 2023-01-25 |
| JP7645185B2 JP7645185B2 (ja) | 2025-03-13 |
Family
ID=65228484
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540589A Active JP7645185B2 (ja) | 2019-01-15 | 2020-01-15 | 変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用 |
| JP2024163874A Pending JP2025000723A (ja) | 2019-01-15 | 2024-09-20 | 変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163874A Pending JP2025000723A (ja) | 2019-01-15 | 2024-09-20 | 変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用 |
Country Status (13)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023246908A1 (zh) * | 2022-06-21 | 2023-12-28 | 四川大学华西医院 | 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用 |
| CN115819614B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于il34的嵌合抗原受体免疫细胞制备及其应用 |
| CN115252764A (zh) * | 2022-08-09 | 2022-11-01 | 南方医科大学 | 一种白介素在制备治疗急性髓系白血病的药物中的应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR520E (fr) | 1901-11-13 | 1903-01-26 | Bermont Victor Etienne | Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5) |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| CA2357538A1 (en) | 1989-03-21 | 1990-10-04 | Wisconsin Alumni Research Foundation | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| EP0753069A1 (en) | 1994-04-15 | 1997-01-15 | Targeted Genetics Corporation | Gene delivery fusion proteins |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| ID29991A (id) | 1998-12-23 | 2001-10-25 | Pfizer Inc Cs | Antibodi monoklonal manusia pada ctla-4 |
| KR100996759B1 (ko) | 1999-08-24 | 2010-11-25 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| HRP20030071B1 (hr) | 2000-07-03 | 2014-01-03 | Bristol-Myers Squibb Company | Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula |
| AR036852A1 (es) | 2001-10-19 | 2004-10-06 | Isotechnika Inc | Preconcentrado de una microemulsion de analogos de ciclosporina, su metodo de preparacion y metodos para producir inmunosupresion |
| CN1729203B (zh) | 2002-10-17 | 2014-02-19 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
| EP2287310B1 (en) * | 2004-07-22 | 2015-05-06 | Five Prime Therapeutics, Inc. | Compositions and methods using MGD-CSF in disease treatment |
| MX2007013978A (es) | 2005-05-09 | 2008-02-22 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos. |
| ES2546333T3 (es) | 2005-07-01 | 2015-09-22 | E. R. Squibb & Sons, L.L.C. | Anticuerpos monoclonales humanos para ligandos 1 (PD-L1) de muerte programada |
| SG153832A1 (en) | 2005-12-20 | 2009-07-29 | Bristol Myers Squibb Co | Stable protein formulations |
| AU2009213738B2 (en) | 2008-02-11 | 2015-01-22 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| PL2350129T3 (pl) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Kompozycje antagonistów PD-1 i sposoby stosowania |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| WO2010117057A1 (ja) | 2009-04-10 | 2010-10-14 | 協和発酵キリン株式会社 | 抗tim-3抗体を用いた血液腫瘍治療法 |
| US8289808B2 (en) | 2009-04-16 | 2012-10-16 | Chevron U.S.A., Inc. | System and method to estimate compressional to shear velocity (VP/VS) ratio in a region remote from a borehole |
| HRP20171653T1 (hr) | 2009-11-24 | 2017-12-15 | Medimmune Limited | Vezna sredstva koja služe ciljano protiv b7-h1 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| ES2682078T3 (es) | 2010-06-11 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-TIM-3 |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| EA031470B1 (ru) | 2013-03-15 | 2019-01-31 | Бристол-Майерс Сквибб Компани | Ингибиторы ido |
| RS57508B1 (sr) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Tech Ltd | 1,2,4-derivati oksadiazola kao imunomodulatori |
| EP3385257A1 (en) | 2013-09-06 | 2018-10-10 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
| ES2710444T3 (es) * | 2014-07-17 | 2019-04-25 | Inst Nat Sante Rech Med | Un polipéptido de interleucina 34 aislado para uso en la prevención del rechazo de trasplante y el tratamiento de enfermedades autoinmunitarias |
| JP2018516933A (ja) * | 2015-06-02 | 2018-06-28 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法 |
| CN106084030B (zh) | 2016-04-25 | 2019-11-08 | 北京大学 | 一种提高白细胞介素il-34热稳定性的方法 |
-
2020
- 2020-01-15 KR KR1020217024902A patent/KR20210121077A/ko active Pending
- 2020-01-15 ES ES20700307T patent/ES3011707T3/es active Active
- 2020-01-15 IL IL284868A patent/IL284868B2/en unknown
- 2020-01-15 EP EP20700307.0A patent/EP3911670B1/en active Active
- 2020-01-15 WO PCT/EP2020/050920 patent/WO2020148338A1/en not_active Ceased
- 2020-01-15 BR BR112021013944A patent/BR112021013944A8/pt unknown
- 2020-01-15 SG SG11202107606VA patent/SG11202107606VA/en unknown
- 2020-01-15 US US17/422,556 patent/US20220098264A1/en active Pending
- 2020-01-15 CA CA3126741A patent/CA3126741A1/en active Pending
- 2020-01-15 JP JP2021540589A patent/JP7645185B2/ja active Active
- 2020-01-15 CN CN202080017907.2A patent/CN113508129B/zh active Active
- 2020-01-15 AU AU2020208909A patent/AU2020208909B2/en active Active
- 2020-01-15 MX MX2021008525A patent/MX2021008525A/es unknown
-
2024
- 2024-09-20 JP JP2024163874A patent/JP2025000723A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11919931B2 (en) | Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3) | |
| US10995131B2 (en) | Libraries of modified fibronectin type III tenth domain-containing polypeptides | |
| US11814679B2 (en) | Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of same | |
| CN114929730A (zh) | 重组肽-mhc复合物结合蛋白及其生成和用途 | |
| HK1248137A1 (zh) | 用於治療癌症的聚乙二醇化白細胞介素-10 | |
| EP2655411A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
| CN107636014A (zh) | 抗癌融合多肽 | |
| CN112105632A (zh) | 细胞因子融合蛋白 | |
| HUP0303534A2 (hu) | Csökkent immunogenitású módosított interferon-béta | |
| JP2020500511A5 (enrdf_load_stackoverflow) | ||
| NZ273813A (en) | Myelin oligodendrocyte glycoprotein autoantigen | |
| JPWO2020148338A5 (enrdf_load_stackoverflow) | ||
| HUP0303309A2 (hu) | Csökkentett immunogenitású módosított interferon-alfa | |
| CN115916251A (zh) | 肽混合物 | |
| CN1494430A (zh) | 免疫原性减弱的经修饰鱼精蛋白 | |
| RU2021124076A (ru) | Мутантный полипептид интерлейкина -34 (IL-34) и его применение в терапии | |
| WO2011147320A1 (zh) | B细胞激活因子拮抗剂及其制备方法与用途 | |
| CN120623341A (zh) | 用于目标蛋白的多价d-肽化合物 | |
| CN118620056A (zh) | Il-2变体及其用途 | |
| CN105330735A (zh) | 一种prrt2蛋白相关的抗原表位肽及其应用 | |
| BR112017020445B1 (pt) | Proteína de fusão, molécula de ácido nucleico, célula hospedeira, método de produção de uma proteína de fusão, uso de uma ou mais proteínas de fusão e composição farmacêutica | |
| CA2497833A1 (en) | A method of modulating cellular activity and molecules for use therein |